Joint 23rd Medicines for Europe – 20th IGBA Annual Conference

Unlocking Pharma Growth – Emerging Markets

by D G Shah Secretary General Indian Pharmaceutical Alliance

> Lisbon 16 June 2017

Indian Pharmaceutical Alliance



IPA: 06/17


Indian Pharmaceutical Alliance Current Members (20) Lupin □ Alembic Mylan □ Alkem Micro □ Cadila Healthcare Natco □ Cadila Pharmaceuticals Panacea Biotech Cipla 🛛 Sun □ Dr Reddy's Torrent Glenmark Unichem □ INTAS USV □ IPCA Wockhardt **J** B Chemicals 3 IPA: 06/17



Indian Pharmaceutical Industry


Pharmacy of the World





McKinsey View of Indian Pharmaceutical Industry

Industry has grown to become 8th largest country globally and continues to have one of the highest growth rates



McKinsey View of Indian Pharmaceutical Industry



Drug Regulatory Regime

Key Issues

□ FDC Ban

IPA: 06/17

- □ Generic Prescribing
- □ Capability Building

Aligning With Global Agencies

Pricing Policy

Implementation Issues

- □ Tweaking Definition of Brand to Inflict Deeper Price Cuts
- Denying/Delaying Price Approvals
- □ Retrospective Pricing: Burden of Compliance
- □ Frequent Price Revisions

IPA: 06/17

Tilting Delicate Balance Between Access and Availability



However, India currently has nascent position in these innovation spaces

Generics ANDA approvals Percent share, 2011-13		Specialty generics		Incremental innovation 505(b)2 approvals Percent share, 2011-13		New molecular entities NCE approvals Percent share, 2011-13	
US	37	India	22	Europe	18	U.K	35
Europe	12	Iceland	0	India	6 8 14	Japan	8
Israel	5	Europe	4	Israel	3	Canada	3
Others	9	Others	10	Others	0	Others	3
Strong position comparable to US, achieved in just 10 year		Strong emerging presence in areas such as dermn, topicals etc.		Position primarily driven by ARVs; Potential to explore incremental innovation in other areas		Limited advances may thus far; Early movement seen in Indian market	





IPA: 06/17

